Respiratory Diseases
Respiratory diseases are a diverse group of illnesses involving the respiratory system from the nose to the lungs. Common types include colds and flu (caused by viruses), bronchitis (inflammation of the bronchial tubes), asthma (chronic inflammatory lung disease), chronic obstructive pulmonary disease (COPD, which includes chronic bronchitis and emphysema), pneumonia (infection of the lungs), tuberculosis (a contagious disease caused by the bacterium Mycobacterium tuberculosis), and lung cancer (a malignant tumor of the lungs). These diseases can be caused by viruses, bacteria, allergens, pollutants, smoking, and other environmental factors.
Currently, drug development for respiratory diseases is focused on the following areas:
- Inflammatory mediators: Anti-inflammatory drugs aimed at reducing the symptoms of inflammatory lung diseases such as asthma and COPD. At the same time, biologics targeting specific inflammatory mediators are being developed, such as anti-IL-5 and anti-IL-13, for the treatment of severe asthma.
- Antimicrobials: New antimicrobial drugs targeting drug-resistant bacteria are critical for treating respiratory infections such as pneumonia.
- Immune checkpoints: Immunotherapies such as PD-1/PD-L1 inhibitors for the treatment of lung cancer.
- Gene therapy: Gene therapy for inherited respiratory diseases, such as cystic fibrosis, is under investigation.
- Tumor markers: Targeted therapies, such as EGFR inhibitors, are being used in the treatment of non-small cell lung cancer.
- Vaccines: Vaccines for respiratory diseases, such as influenza and pneumococcal vaccines, are continually being updated to adapt to pathogen mutations.
Respiratory Diseases Drug Targets
Respiratory Diseases Drug Target Related Products
● Target Proteins
Measured by its binding ability in a functional ELISA. Immobilized PD-1 at 2 μg/ml can bind Anti-PD-1 recombinant antibody, the EC50 of human PD-1 protein is 6.087-7.854 ng/ml.
Measured by its binding ability in a functional ELISA. Immobilized PD-L1 at 2 μg/ml can bind Anti- PD-L1 mouse monoclonal antibody (CSB-MA878942A1m, antigen from E.coli), the EC50 of human PD-L1 protein is 1.252-1.653 ng/mL
Human EGF protein captured on COOH chip can bind Human EGFR protein, his and Myc tag (CSB-MP007479HU) with an affinity constant of 11.9nM as detected by LSPR Assay.
SARS-CoV-2 Spike protein RBD his/sumostar tag (CSB-YP3324GMY1) captured on COOH chip can bind Human ACE2 protein Fc tag (CSB-MP866317HU) with an affinity constant of 100 nM as detected by LSPR Assay.
Measured in cell activity assay using U937 cells, the EC50 for this effect is 190.2-298.6 ng/ml.
Measured by its binding ability in a functional ELISA. Immobilized CD152 at 2 μg/ml can bind Anti-CD152 rabbit monoclonal antibody (CSB-RA213310A0HU), the EC50 of human CD152 protein is 27.14-34.82 ng/ml.
Measured by its binding ability in a functional ELISA. Immobilized Human IL4 (CSB-MP011659HU) at 2μg/mL can bind biotinylated Human IL4R，the EC50 is 12.68-14.23 ng/mL.
Measured by its binding ability in a functional ELISA. Immobilized HER2 at 2 μg/ml can bind Trastuzumab, the EC50 is 2.179-2.825 ng/ml.
